Upload
hayden-worsley
View
216
Download
0
Embed Size (px)
Citation preview
Barriers to Treatment
Chip Wilmot, MD PhD
Emory University
Disclosure
• Member, Data Safety Monitoring Board for studies involving Idebenone (Santhera Pharmaceuticals)
“Why Don’t We Have A Treatment for Ataxia Yet?”
-anonymous at NAF AMM 2012
“Why Don’t We Have A Treatment for Ataxia Yet?”
-anonymous at NAF AMM 2012and FAPG and GAASG
and my clinic and …
“Why Don’t We Have A Treatment for Ataxia Yet?”
-Chip Wilmot, MD, PhDEmory University
Treatment
the care and management of a patient to combat, ameliorate, or prevent a disease, disorder, or injury.
Cure
A method or course of medical treatment used to restore health.
Cure
A method or course of medical treatment used to restore health.
Don’t forget about prevention (at least for dominant SCA’s)
Treatment
-Symptomatic -pain, cramps, depression, mobility
-Disease-modifying-slowing the rate of progression
“Why Don’t We Have A Treatment for Ataxia Yet?”
-Developing a treatment is HARD
“Why Don’t We Have A Treatment for Ataxia Yet?”
-Developing a treatment is HARD-Expectations for treatments can be unrealistic
“Why Don’t We Have A Treatment for Ataxia Yet?”
-Developing a treatment is HARD-Expectations for treatments can be unrealistic-We are doing a good job, but …
“Why Don’t We Have A Treatment for Ataxia Yet?”
-Developing a treatment is HARD-Expectations for treatments can be unrealistic-We are doing a good job, but …- … there are certainly ways to facilitate treating ataxia
Clinical Disease
Treat Human Disease
Clinical Disease
Treat Human Disease
Etiology (Cause)
Model Disease
Treat Model
Clinical Disease
Treat Human Disease
Etiology (Cause)
Model Disease
Treat Model
Clinical Disease
Treat Human Disease
Etiology (Cause)
Model Disease
Treat Model
Clinical Disease
Treat Human Disease
Etiology (Cause)
Model Disease
Treat Model
Clinical Disease
Etiology (Cause)
Model Disease
Treat Model
Treat Human DiseaseTreat Symptoms
Treat Disease
What is needed to develop effective treatments?
1. Knowledge of the disease pathophysiology2. A way to measure the disease3. An understanding of the natural history of the
disease4. Research Infrastructure
What is needed to develop effective treatments?
1. Knowledge of the disease pathophysiology
-the cause –
-ataxia genes galore-downstream consequences, e.g mitochondrial dysfunction in FRDA-insights into cerebellar (dys)function
What is needed to develop effective treatments?
1. Knowledge of the disease pathophysiology-the cause
-relevant models-mice, fruit flies, worms, etc.
What is needed to develop effective treatments?
1. Knowledge of the disease pathophysiology-the cause-relevant models
-candidate treatments-EPI-743, pioglitazone, lithium, riluzole, VEGF
FRDA Timeline
20001863 1980 1990 2010
First clinical description Gene Discovered
Outcome Measures Validated
Natural History Studies Begun
Treatment Trials
What is needed to develop effective treatments?
1. Knowledge of the disease pathophysiology-the cause-relevant models-candidate treatments
2.A way to measure the disease-clinical scales, instrumented
measures, biomarkers
What is needed to develop effective treatments?
1. All the preliminary info:-the cause-relevant models-candidate treatments
2. A way to measure the disease
3. An understanding of the natural history of the disease
-rate of progression-variability
What is needed to develop effective treatments?
1. All the preliminary info:-the cause-relevant models-candidate treatments
2. A way to measure the disease3. An understanding of the natural history of the disease
-rate of progression-variability
4. Research Infrastructure-ataxia centers-$$$-research subjects
IS THIS TREATMENT EFFECTIVE?
IS THIS TREATMENT EFFECTIVE?
IS THIS TREATMENT EFFECTIVE?
Copyright restrictions may apply.
Lynch, D. R. et al. Arch Neurol 2010;67:941-947.
How can the likelihood of a positive trial be improved?
How can the likelihood of a positive trial be improved?
1. Reduce variability-large numbers-homogeneous study population-precise measures
How can the likelihood of a positive trial be improved?
1. Reduce variability-large numbers-homogeneous study population-precise measures
2. Increase trial timeline
How can the likelihood of a positive trial be improved?
1. Reduce variability-large numbers-homogeneous study population-precise measures
2. Increase trial timeline3. Use a more effective treatment
How can the likelihood of a positive trial be improved?
1. Reduce variability-large numbers-homogeneous study population-precise measures
2. Increase trial timeline3. Use a more effective treatment
Note: These are not always possible
What can be done to facilitate treatment
development?
1. Learn from other diseases
ALS
ALS vs. ataxia-ALS is 90% sporadic; pathophysiology not well understood-Quicker progression, more definite clinical measures
What can be done to facilitate treatment
development?
1. Learn from other diseases2. Don’t disregard low lying fruit!!!
-non-sexy treatments ARE available
-(e.g. ALS PEG tubes and ventilatory support)
What can be done to facilitate treatment
development?
1. Learn from other diseases2. Don’t disregard low lying fruit!!!
-non-sexy treatments ARE available
What can be done to facilitate treatment
development?
1. Learn from other diseases2. Don’t disregard low lying fruit!!!
-non-sexy treatments ARE available3. Never underestimate the power of dedicated action
What can be done to facilitate treatment
development?
1. Learn from other diseases2. Don’t disregard low lying fruit!!!
-non-sexy treatments ARE available3. Never underestimate the power of dedicated action
Thanks
-Patients, families-Coordinators: Bettye Robinson RN, Sue Gronka RN-Colleagues-NAF, FARA, MDA, NIH